Prospective REgistry of Targeted RadionucLide TherapY in Patients With mCRPC (REALITY Study)

Overview

This prospective registry aims to assess outcome and toxicity of targeted radionuclide therapies in patients with advanced prostate cancer in clinical routine. While the major investigated treatment modality is prostate-specific membrane antigen (PSMA)-targeted radioligand therapy, also other radionuclide therapies such as Ra223 and liver-directed radioembolization are included. The investigators believe that prospectively assessed long-term outcome data on implementation of radionuclide therapy, especially in the palliative setting of advanced mCRPC, help to better define the real benefits and risks of the respective treatment modalities for patients regarding survival and quality-of-life.

Full Title of Study: “REALITY Study: Analysis of a Prospective REgistry to Assess Outcome and Toxicity of Targeted RadionucLide TherapY in Patients With mCRPC in Clinical Routine.”

Study Type

  • Study Type: Observational [Patient Registry]
  • Study Design
    • Time Perspective: Prospective
  • Study Primary Completion Date: December 31, 2024

Detailed Description

Targeted radionuclide therapy is comprised of different modalities that may be applied in advanced prostate cancer, either targeting bone metastases (mainly using Radium-223), any type of metastases with PSMA-expression (Lutetium-177 and Actinium-225 labelled radioligands) or loco-regionally applying internal radiation (Yttrium-90 microspheres) to metastatic liver disease. While in Germany, each form of treatment is used in clinical routine, data is sparse regarding the real benefits and risks of respective modalities, also when used in a sequential order. As an example, patients receiving Ra223 treatment may later undergo PSMA targeted radioligand therapy, with little data available on dependent response relationships or cumulative risks. Prospective assessment of outcomes and toxicities in a radionuclide therapy registry is apparently superior over retrospective analyses of selected patient populations. The goal of the REALITY study is to gain a better understanding of the real-life clinical application of radionuclide therapies, with a focus on PSMA-targeted radioligand therapy in a high-volume treatment centre, and the impact of each treatment for patient outcome. Based on primary and secondary outcome measures the potential prediction of treatment benefit by baseline patient and tumor characteristics, and early changes of biomarkers will be of interest.

Arms, Groups and Cohorts

  • Lu177 PSMA RLT
    • Lutetium-177 prostate-specific membrane antigen (Lu177 PSMA) radioligand therapy (RLT) according to standard local protocol
  • Ac225 PSMA RLT
    • Actinium-225 prostate-specific membrane antigen (Ac225 PSMA) radioligand therapy (RLT) according to standard local protocol
  • Tandem Lu177 / Ac225 PSMA RLT
    • Combined Lu177 / Ac225 PSMA radioligand therapy according to standard local protocol
  • Ra223 chloride
    • Bone-targeted Radium-223 (Ra223) radionuclide therapy in standard application
  • Sm153 EDTMP
    • Bone-targeted Samarium-153 (Sm153) EDTMP radionuclide therapy in standard application
  • Y90 microshperes
    • Radioembolization with yttrium-90 (Y90) microspheres, standard methodology

Clinical Trial Outcome Measures

Primary Measures

  • PSA response
    • Time Frame: up to 10 years
    • Best PSA response and PSA response after 3 months from start of radionuclide therapy
  • PSA-PFS
    • Time Frame: up to 10 years
    • PSA-based progression-free survival (PFS) according to PCWG3 criteria. From date of start of radionuclide therapy until documented and confirmed PSA-progression
  • OS
    • Time Frame: up to 10 years
    • Overall survival. From date of start of radionuclide therapy until the date of death from any cause assessed
  • Toxicity (adverse events)
    • Time Frame: up to 10 years
    • All toxicity occurring after start of radionuclide treatment will be registered according to the Common Terminology Criteria for Adverse Events (CTCAE version 4.03).
  • Toxicity-related discontinuation of radionuclide treatment
    • Time Frame: up to 10 years
    • Rate of toxicity-related discontinuation of radionuclide therapy

Secondary Measures

  • Conventional imaging response
    • Time Frame: up to10 years
    • Response to radionuclide therapy based on conventional imaging according to RECIST 1.1
  • Molecular imaging response
    • Time Frame: up to 10 years
    • Response to radionuclide therapy based on molecular imaging
  • Quality-of-life in patients receiving radionuclide therapy
    • Time Frame: up to 10 years
    • Quality-of-life assessed from start of radionuclide treatment by EORTC QLQ-C30 questionaires
  • Pain control achieved by radionuclide therapy
    • Time Frame: up to 10 years
    • Based on VAS-BPI patient questionaires from start of radionuclide treatment
  • Absorbed doses achieved by radionuclide therapy
    • Time Frame: up to 10 years
    • Absorbed doses in Gy/GBq based on intra- / posttherapeutic dosimetry when available

Participating in This Clinical Trial

Inclusion Criteria

  • Signed informed consent form (Registry Study Inclusion Form) Exclusion Criteria:

  • Inability or unwillingness to provide informed consent

Gender Eligibility: Male

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Universität des Saarlandes
  • Provider of Information About this Clinical Study
    • Principal Investigator: Samer Ezziddin, MD, Director, Dept. of Nuclear Medicine – Universität des Saarlandes
  • Overall Official(s)
    • Samer Ezziddin, MSc, MD, PhD, Principal Investigator, Universität des Saarlandes
  • Overall Contact(s)
    • Samer Ezziddin, MSc, MD, PhD, +49 6841 16 22201, PSMA@uks.eu

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.